

General information about company	
Name of The Company	KILITCH DRUGS (INDIA) LIMITED
BSE Scrip Code	524500
NSE Symbol	KILITCH
MSE Symbol	NA
Date of Start of Financial Year	01-04-2023
Date of End of Financial Year	31-03-2024
Reporting Period	Second half yearly
Date of Start of Reporting Period	01-10-2023
Date of End of Reporting Period	31-03-2024
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Related party transactions

Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		Addition to loans, details
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	
												Nature of indebted (loan/ issuance debt/ any other etc.	
1	Kilitch Drugs India Ltd	AAACK2917R	Mukund Mehta	AAAPM5972F	Managing Director	Remuneration			NA	32.5	0	0	
2	Kilitch Drugs India Ltd	AAACK2917R	Bhavin Mehta	AFOPM2923F	Wholetime Director	Remuneration			NA	45.5	0	0	
3	Kilitch Drugs India Ltd	AAACK2917R	Mira Mehta	AGJMP3218R	Wholetime Director	Remuneration			NA	13	0	0	
4	Kilitch Drugs India Ltd	AAACK2917R	Sunil Jain	AHMPJ8872E	Chief Financial Officer	Remuneration			NA	8.71	0	0	
5	Kilitch Drugs India Ltd	AAACK2917R	Pushpa Nyoupane	AQMPN8988L	Company Secretary	Remuneration			NA	3.06	0	0	
6	Kilitch Drugs India Ltd	AAACK2917R	Hemang Jagdish Engineer	AAAPE0506B	Non Executive and Independent Director	Any other transaction	Sitting Fees		NA	0.15	0	0	
7	Kilitch Drugs India Ltd	AAACK2917R	V. S. Rajan	AABPR7564D	Non Executive and Independent Director	Any other transaction	Sitting Fees		NA	0.02	0	0	
8	Kilitch Drugs India Ltd	AAACK2917R	V. K. Murti	ADPTK1977E	Non Executive and Independent Director	Any other transaction	Sitting Fees		NA	0.1	0	0	
9	Kilitch Drugs India Ltd	AAACK2917R	NBZ Healthcare LLP	AAKFN2329R	Few Directors are Partner	Purchase of goods or services		250	NA	97.15	0	97.15	
10	Kilitch Drugs India Ltd	AAACK2917R	NBZ Healthcare LLP	AAKFN2329R	Few Directors are Partner	Advance		1200	NA	-536.88	960.98	424.1	
11	Kilitch Drugs India Ltd	AAACK2917R	Kilitch Company Pharma Limited	AAACK9966A	Few Directors are Director	Advance		50	NA	0.21	0.77	0.98	
12	Kilitch Drugs India Ltd	AAACK2917R	Kilitch Estro Biotech PLC	ZZZZZ9999Z	Foreing Subsidiary	Advance		250	NA	0	4263.77	4263.77	
13	Kilitch Drugs India Ltd	AAACK2917R	Monarchy Healthserve Pvt Ltd	AAECM9668H	Wholly Owned Subsidiary	Advance		100	NA	1.58	35.97	37.55	

-334.9

Total value of transaction during the

